Alflutinib Recruiting Phase 3 Trials for Metastatic Non-Small Cell Lung Cancer / Advanced Non-Small Cell Lung Cancer (NSCLC) / EGFR Exon 20 Mutations Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT05607550Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)